Small molecule high throughput screen using AstraZeneca facilities (Grant)
Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots. There are two funding opportunities per year that are open to all targets.
Read the official page on Find a grant ↗Start an application ↗ Get new grants like this
- Funder
- UK Research and Innovation, Medical Research Council
- Where
- 🇬🇧 United Kingdom
- Status
- Closes 8 Sep 2027 · 292 days left
- Opened
- 10 Sep 2026
- Funding
- £1–£270k per award (£1m in total)
- Who can apply
- Most organisations
- Topics
- Science & research Innovation & technology Arts & culture
About this grant
The closing date has been extended to 8 September 2027 4:00pm UK time.
Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots.
Objectives
Demand management
Demand management is being applied to this funding opportunity. Further details are provided in the ‘who can apply’ section.
Scope
The small molecule HTS using AstraZeneca facilities funding opportunity aims to support academic researchers in discovering potential starting points for small molecule medicinal drugs.
Academic researchers will benefit from unprecedented access to over two million molecules in AstraZeneca’s compound library, as well as its state-of-the-art high-throughput screening facilities.
Medical Research Council (MRC) will provide funding to support up to four projects per year. As capacity is limited, projects will be prioritised for funding and for time slots within the facility. The timeframe for commencement of the studies will vary, although the expectation is within six months of the funding decision.
AstraZeneca may offer to fund a project in its entirety if, based on the application, it considers that route to be the most appropriate funding mechanism for that individual study. In such cases, these will be taken forward through direct collaboration with the company without any further MRC involvement. Applicants who do not wish to accept this offer may continue to seek MRC support through the initiative.
AstraZeneca will provide technical input to support assay optimisation, investigation of alternative readout technologies and pilot HTS screen, prior to transfer of the assay to the HTS platform. Depending on the results of the optimisation, a compound set of between 100,000 and 1 million of the library will be screened.
Minimum assay development guidelines
There are a number of minimum assay development guidelines which when considered as a whole will need to provide evidence that a screen could be conducted. Funds are provided to complete the assay development, so a less well-developed assay is not a barrier to your application being competitive.
Duration
The duration of this award is typically 15 months. However, the duration can be from 12 (minimum) to a maximum of 18 months.
Funding available
he full economic cost (FEC) of your project can be up to £270,000 (£250,000 cost to MRC).
We will fund 100% FEC of the work conducted at AstraZeneca.
We will fund 80% FEC of any work conducted at the research organisation or related to staff costs, subsistence and travel.
What we will fund
We will fund costs related to staff and consumables incurred at AstraZeneca for the optimisation and execution of the HTS. These include:
£20,000 (100% FEC exceptions) for optimisation and establishment of an HTS
£150,000 (100% FEC exceptions) for execution of the HTS
cost of travel, accommodation and subsistence for a host institution researcher to work at AstraZeneca in Cambridge for three months (80% FEC)
costs for elements of the screening cascade that cannot be undertaken at AstraZeneca and must be undertaken at the host organisation (80% FEC)
minimal percentage of full-time equivalent for the project lead (80% FEC)
What we will not fund
We will not fund conference attendance.
Supporting skills and talent
This funding opportunity highly encourages a researcher from the host institution to embed themselves at the AstraZeneca facilities in Cambridge for a period of up to three months total. This will help with the establishment of the assay and conducting the HTS.
The three months can be split into shorter chunks based on requirements of the project. Any application not requesting funding to support a visit to the AstraZeneca facility should state why it is not viable. However, this will not affect the evaluation of the merits of the project. It is understood that not all researchers can accommodate a prolonged period away from home.
We encourage you to follow the principles of the Concordat to Support the Career Development of Researchers and the Technician Commitment.
Trusted Research and Innovation (TR&I)
UKRI is committed in ensuring that effective international …
Dates
Assessment process
We will assess your application using the following process
Panel
A panel of experts will be invited to assess the quality of your application and rank it alongside other applications after which the panel will make a funding recommendation.
AstraZeneca will have a nominated member on the panel of experts and be involved in the funding decision. Their input will be limited to confirmation that:
projects are technically feasible
projects would pass the gating criteria for internal projects
there are no third-party agreements preventing AstraZeneca from undertaking the project
no equivalent screen has been conducted as part of AstraZeneca’s internal research and development programme, or through any prior open innovation collaboration
This funding opportunity will no longer seek external peer review comments.For more information on how we prioritise applications for funding please visit How we make decisions.
Timescale
We aim to complete the assessment process within three months of receiving your application.
Feedback
If your application was discussed by a panel, we will give feedback with the outcome of your application.
Principles of assessment
We support the San Francisco declaration on research assessment and recognise the relationship between research assessment and research integrity.
Find out about the UKRI principles of assessment and decision making.
Using generative artificial intelligence (AI) in expert review
Generative AI may be used only for the purpose of language refinement during application assessment. When using generative AI to refine the language of a review, expert reviewers and panellists must ensure that:
no part of the application being assessed is entered into a generative AI tool
no personal information from the application is disclosed
generative AI is not tasked with understanding, summarising or evaluating the application’s content
Expert reviewers and panellists must also:
comply with relevant intellectual property and data protection legislation
not take into account or speculate within their assessment whether generative AI has been used to develop the application
For more detail see our policy on the use of generative AI.
Sharing data with co-funders
Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), will need to share the application and any personal information that it contains with AstraZeneca so that they can participate in the assessment process. For more information on how AstraZeneca uses personal information, visit AstraZeneca’s privacy notice.
We reserve the right to modify the assessment process as needed.
Assessment areas
The assessment areas we will use are:
vision of the project
approach to the project (including data management)
capability of the applicant or applicants and the project team to deliver the project
resources requested to do the project
ethical and responsible research and innovation considerations of the project
Find details of assessment questions and criteria under the ‘Application questions’ heading in the ‘How to apply’ section.
The following information provides a guide on how high, medium and low feasibility will be assessed.
Translatability and or readout relation to mechanism of intervention, including:
high feasibility: direct readout relevant to mechanism of intervention
medium feasibility: readout indirect to mechanism of intervention
low feasibility: connection to target perturbation uncertain
Reagent generation and supply (technical aspects), including:
high feasibility: in-house precedent or commercially available with appropriate quality control
medium feasibility: in-house or external precedent for related or similar targe
high feasibility: no precedent for target or family members or known to be challenging
Reagent generation and supply (timelines, resources and cost), including:
high feasibility: timelines will fit objectives
medium feasibility: …
Eligibility
This opportunity is open to organisations with standard eligibility. Check if your organisation is eligible.
Who is eligible to apply
To be eligible to apply for this funding opportunity you must show that you will direct the project and be actively engaged in the work.
For applicants who do not have a contract of employment for the duration of the proposed project, by submitting an application the research organisation is confirming, if it is successful:
contracts will be extended beyond the end date of the project
all necessary support for the project and the applicants will be provided, including mentorship and career development for early career researchers
Demand management
You can only submit one application as project lead to this funding opportunity.
Resubmissions
We will not accept uninvited resubmission of applications that were submitted after 1 April 2026 to Medical Research Council (MRC), the rest of UK Research and Innovation (UKRI) or any other funder. An uninvited resubmission is an application that was previously unsuccessful and has been submitted again without being invited by MRC. This includes applications that are unchanged, minimally revised, or substantially the same as the original submission. Uninvited resubmissions will be rejected.
You should contact us if you are unsure whether your application is a resubmission. Find contacts in the ‘contact details’ section.
Who is not eligible to apply
Research applications that are led by commercial entities are not eligible. Applications may not include collaborations with additional commercial parties.
You are also not eligible to apply for this funding opportunity as a project lead if you are based at an international research organisation. This does not include MRC Unit The Gambia or MRC/UVRI Uganda Research Unit at the London School of Hygiene and Tropical Medicine that are eligible to apply as project lead.
Equality, diversity and inclusion
We are committed to achieving equality of opportunity for all funding applicants. We encourage applications from a diverse range of researchers.
We support people to work in a way that suits their personal circumstances. This includes:
career breaks
support for people with caring responsibilities
flexible working
alternative working patterns
UKRI can offer disability and accessibility support for UKRI applicants and grant holders during the application and assessment process.
Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →
Applying? Read how to write a winning grant proposal.
Contains public sector information licensed under the Open Government Licence v3.0 (Find a grant). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.